M
MacroGenics, Inc. (MGNX)
NMS – Real vaqt narxi. Valyuta: USD
4.81
+0.15 (3.22%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.70
-0.11 (-2.29%)
Bozordan keyin: Jun 26, 2026, 7:46 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
4.81
+0.15 (3.22%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.70
-0.11 (-2.29%)
Bozordan keyin: Jun 26, 2026, 7:46 PM EDT
MacroGenics, Inc., klinik davrdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saratonni davolash uchun antitelalarga asoslangan terapevtik vositalarni kashf qiladi, ishlab chiqadi, ishlab chiqaradi va tijoratlashtiradi. Kompaniyaning mahsulot quvuri orasida lorigerlimab, mCRPCni davolash uchun PD-1 va CTLA-4 nazorat nuqtasi inhibitörlerine yo'naltirilgan bispesifik DART molekulasi va 2-bosqichli klinik sinovlarda bo'lgan, shuningdek, platina-rezistent tuxumdon saratoni va 1-bosqichli klinik sinovlarni yakunlagan yorug' hujayrali ginekologik saratonni davolash uchun dosetaksel mavjud; B7-H3 ni nishonga oladigan va yangi topoisomerase I inhibitori (TOP1i) asosidagi linker-yukni yetkazib beradigan ADC MGC026; qattiq o'smalarni davolash uchun ADAM9 ni nishonga oladigan va yangi TOP1i asosidagi linker-yukni yetkazib beradigan antitelali-dorivor konjugatlar (ADC) MGC028, ular 1-bosqichli klinik sinovlarda; bir nechta qattiq o'smalarda ifodalangan noma'lum antigenni nishonga oladigan va preklinik sinovlarda bo'lgan ADC molekulasi MGC030. Kompaniya T-hujayralarni faollashtiruvchi dasturlarni ham ishlab chiqmoqda. Kompaniya TerSera Therapeutics LLC; Incyte Corporation; va Gilead Sciences, Inc. bilan hamkorlik qiladi. MacroGenics, Inc. 2000 yilda tashkil etilgan va uning shtab-kvartirasi Merilend shtatining Rokvill shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ezio Bonvini M.D. | Senior VP of Research & Chief Scientific Officer |
| Dr. Frank George Perabo FEBU, M.D., Ph.D. | Vice President & Interim Head of Clinical Development |
| Dr. Thomas M. Spitznagel Ph.D. | Senior Vice President of Technical Operations |
| Mr. Eric Blasius Risser | CEO, President & Director |
| Mr. Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning |
| Mr. James Karrels | Senior VP & CFO |
| Mr. Jeffrey Stuart Peters J.D. | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer |
| Mr. Steve Harig | Senior Vice President of Human Resources |
| Ms. Beth Smith | VP, Controller & Treasurer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-20 | 8-K | mgnx-20260519.htm |
| 2026-05-13 | 8-K | mgnx-20260513.htm |
| 2026-05-13 | 10-Q | mgnx-20260331.htm |
| 2026-05-12 | 8-K | mgnx-20260511.htm |
| 2026-05-04 | 8-K | mgnx-20260501.htm |
| 2026-04-22 | DEFA14A | defa14aamendment.htm |
| 2026-04-08 | DEFA14A | defa14a2026.htm |
| 2026-04-08 | DEF 14A | mgnx-20260407.htm |
| 2026-04-08 | 8-K | mgnx-20260408.htm |
| 2026-03-09 | 8-K | mgnx-20260309.htm |